Search Results
You are looking at 1 - 1 of 1 items for
- Author: K. Trieb x
- Refine by access: All content x
Search for other papers by K. Trieb in
Google Scholar
PubMed
Search for other papers by K. Dorfinger in
Google Scholar
PubMed
Search for other papers by N. Neuhold in
Google Scholar
PubMed
Search for other papers by E. Selzer in
Google Scholar
PubMed
Search for other papers by A. Wilfing in
Google Scholar
PubMed
Search for other papers by S. Czernin in
Google Scholar
PubMed
Search for other papers by M. Hermann in
Google Scholar
PubMed
Search for other papers by B. Niederle in
Google Scholar
PubMed
Search for other papers by A. Gessl in
Google Scholar
PubMed
Search for other papers by H. Vierhapper in
Google Scholar
PubMed
Search for other papers by M. Freissmuth in
Google Scholar
PubMed
Search for other papers by B. Grubeck-Loebenstein in
Google Scholar
PubMed
ABSTRACT
In the last decade, suramin has become known for its antiproliferative, differentiation-inducing effects on cells and has been successfully used in the therapy of cancer patients. The present study was undertaken to investigate the effects of suramin on normal human thyroid cells in primary monolayer culture and to analyse whether it also affected cells from thyroid carcinomas. The results show that suramin, at concentrations similar to serum levels obtainable during therapy, inhibited the proliferation of thyroid cells as well as the secretion of thyroglobulin. It suppressed the activation of adenylyl cyclase in thyroid membranes and decreased the immunogenicity of the cells by reducing their surface expression of HLA-DR and ICAM-1. Although the morphology of differentiated thyroid cells remained unaffected by suramin, morphological changes compatible with differentiation were observed in cells from undifferentiated thyroid carcinomas when suramin was added to the culture medium. In conclusion, the data demonstrate that suramin has pronounced in-vitro effects on normal and neoplastic thyroid cells. It may, therefore, also be effective in patients with thyroid cancer, for whom no other form of treatment is available.
Journal of Endocrinology (1992) 134, 505–511